Fox Business - The Power to Prosper
Search Site

Novo Nordisk

Investing in stocks that won’t go out of style

Gabelli Funds portfolio manager Howard Ward on stocks that will consistently boost investors’ portfolios.

Read More

  1. Top insulin maker Novo caught up in China's widening drug probes

    Chinese authorities have visited a site operated by Danish drugmaker Novo Nordisk A/S , the world's biggest maker of insulin, in the latest sign of a widening invest...

  2. China drug sector probe widens as Novo site visited

    Chinese authorities have visited a site operated by Danish drugmaker Novo Nordisk A/S , the world's biggest maker of insulin, the latest evidence of a widening inves...

  3. Weekly Preview: Earnings Season Nears The End, China in Focus

    Economic data and central bank meetings will dominate financial news again next week as the Bank of Japan and Reserve Bank of Australia hold their monthly policy mee...

  4. Leadership Lessons from the Paula Deen Controversy

    I told myself not to get involved in the whole Paula Deen mess. I said to myself, "It's a train wreck. She's radioactive. Let it go and just walk away."In the end, I...

  5. Paula Deen's Crumbling Empire

    FBN's Diane Macedo breaks down Paula Deen's sponsorship problems.

  6. Taco Bell Beefs Up Its Menu

    FBN's Charles Payne breaks down late-morning market news.

  7. EUROPE MARKETS: Europe Stocks Key Off Asia Gains; Banks Rally

    European stock markets posted solid gains on Tuesday, with banks in the driver's seat, as investors took inspiration from Asia, where a weaker yen spurred a rally fo...

  8. Novo Nordisk : Liraglutide Leads to Weight Loss in Study

    Danish pharmaceutical company Novo Nordisk A/S (NOVO-B.KO) Thursday said treatment with its drug liraglutide led to an average 8% weight loss in patients in a 56-wee...

  9. Novo Buys Xellia Pharmaceuticals for $700 Million

    Denmark's privately-held holding company Novo A/S said Tuesday it has acquired Xellia Pharmaceuticals for $700 million from 3i Group PLC (III.LN) and other sharehold...

  10. Rev Run’s new mission

    More than 25 percent of Americans are at risk for developing type 2 diabetes, but many of them don’t even know it. Hip-hop legend and ambassador for the “Ask.Screen.Know” campaign, Rev Run, sat down with Dr. Manny to talk about why he’s made it his mission get people screened

  11. Novo Nordisk Net Profit Up As Insulin Sales Surge

    Denmark's Novo Nordisk A/S (NOVO-B.KO), the world's largest maker of insulin, Wednesday posted a forecast-beating first-quarter net profit rise of 28%, helped by str...

  12. Mexico Hit With a Spike in Diabetes Cases

    An alarming number of Mexicans are being diagnosed with diabetes, making the country a priority market for tackling a disease that is exploding in developing countri...

  1. Novo Nordisk Upgraded to 'Buy'

    Novo Nordisk (NYSE:NVO) was handed an upgrade to "buy" from "hold" on Tuesday from Austria's Erste Group, helping to boost its shares 1%.The Denmark-based drug giant...

  2. European Stocks Eye Weekly Loss Ahead of U.S. Jobs Data

    European stock markets headed lower on Friday, with the benchmark index heading for its first weekly loss since January, as investors remained cautious ahead of nonf...

  3. European ETFs Flying Under The Radar

    The S&P 500 hit a new all-time high on Monday, and the NASDAQ is trading at the best level in 13 years.Both indices are in the midst of a strong bull market -- but t...

  4. Lilly Pumps $700M into Insulin Manufacturing

    Eli Lilly (NYSE:LLY) is increasing its annual investment in insulin production by another $700 million as it looks to help thwart the growing number of diabetes case...

  5. Time To Consider Investing In Scandinavia (EWD, EFNL, NORW, EDEN, GXF)

    The woes in Western Europe were greatly documented during the financial crisis a few years ago. The PIIGS were the countries at the greatest risk of imploding and af...

  6. Novo Nordisk Rises 1.6% After FDA Approval

    Shares of Novo Nordisk AS climbed 1.6% on Wednesday after the Danish drug maker said the U.S. Food and Drug Administration approved its Novoeight drug for use in adu...

  7. Finding the Opportunities for Investors

    Raymond James Chief Investment Strategist Jeff Saut on the stocks to boost investors’ portfolios.

‹ Prev12345Next ›
Freebase CC-BY
Source: Novo Nordisk on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL